Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of Alto Neuroscience, Inc. common stock on an amended Schedule 13G (Amendment No. 2). They report beneficial ownership of 785,000 shares of common stock, representing 2.2% of the class, held through a fund and a managed account advised by Vestal Point Capital.
All 785,000 shares are reported with shared voting and dispositive power and no sole power. The ownership percentage is based on 35,093,940 shares outstanding as of May 8, 2026, as stated in Alto Neuroscience’s Form 10-Q. The filers state that the Schedule 13G should not be construed as an admission of beneficial ownership for Section 13 purposes and confirm they own 5% or less of the class.
Positive
None.
Negative
None.
Key Figures
Shares beneficially owned:785,000 sharesOwnership percentage:2.2%Shares outstanding:35,093,940 shares+3 more
6 metrics
Shares beneficially owned785,000 sharesCommon stock beneficially owned by Vestal Point Capital and Ryan Wilder
Ownership percentage2.2%Percentage of Alto Neuroscience common stock class beneficially owned
Shares outstanding35,093,940 sharesAlto Neuroscience common stock outstanding as of May 8, 2026
Shared voting power785,000 sharesShares over which the reporting persons have shared power to vote
Shared dispositive power785,000 sharesShares over which the reporting persons have shared power to dispose
Ownership threshold status5 percent or lessReporting under Item 5 as owning 5 percent or less of the class
"not be construed as an admission that any Reporting Person is, for the purposes of Section 13, the beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting powerregulatory
"Shared Voting Power 785,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared Dispositive Power 785,000.00"
investment adviserfinancial
"the investment adviser to a certain fund and a managed account"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
FAQ
What ownership stake in Alto Neuroscience (ANRO) does Vestal Point Capital report?
Vestal Point Capital and Ryan Wilder report beneficial ownership of 785,000 shares of Alto Neuroscience common stock, representing 2.2% of the outstanding class, held through a fund and a managed account they advise.
How many Alto Neuroscience (ANRO) shares are outstanding for the 13G/A calculation?
The reported 2.2% ownership is calculated using 35,093,940 shares of Alto Neuroscience common stock outstanding as of May 8, 2026, as disclosed in the company’s Form 10-Q for the quarter ended March 30, 2026.
Does Vestal Point Capital have sole or shared voting power over ANRO shares?
Vestal Point Capital and Ryan Wilder report 0 shares with sole voting power and 785,000 shares with shared voting power, matching the number of shares over which they report shared dispositive power.
Is Vestal Point Capital a 5% or larger holder of Alto Neuroscience (ANRO)?
No. Vestal Point Capital and Ryan Wilder state that they beneficially own 5 percent or less of Alto Neuroscience’s common stock, reporting an ownership percentage of 2.2% of the outstanding shares.
Who are the reporting persons in this Alto Neuroscience (ANRO) Schedule 13G/A?
The reporting persons are Vestal Point Capital, LP, a Delaware limited partnership acting as investment adviser to a fund and an account, and Ryan Wilder, its Chief Investment Officer and Managing Partner, who reports with respect to the same shares.
What powers over Alto Neuroscience (ANRO) shares do the reporting persons disclose?
They disclose 0 shares with sole voting and dispositive power and 785,000 shares with shared voting power and shared dispositive power, reflecting the holdings of the Vestal Point fund and managed account.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Alto Neuroscience, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
02157Q109
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
Vestal Point Capital, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
785,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
785,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
785,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.2 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
02157Q109
1
Names of Reporting Persons
Ryan Wilder
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
785,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
785,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
785,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.2 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Alto Neuroscience, Inc.
(b)
Address of issuer's principal executive offices:
650 Castro Street, Suite 450, Mountain View, California 94041
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Alto Neuroscience, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and
(ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.
(c)
Citizenship:
The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
02157Q109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 35,093,940 shares of Common Stock outstanding as of May 8, 2026, as reported in the Company's Quarterly Report on the Form 10-Q for the quarterly period ended March 30, 2026, filed with the Securities and Exchange Commission on May 13, 2026.
(b)
Percent of class:
2.2 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vestal Point Capital, LP
Signature:
/s/ Ryan Wilder
Name/Title:
By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
